A Phase I Study of Ipilimumab (Anti-CTLA-4) in Children, Adolescents and Young Adults With Treatment Refractory Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 10 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ipilimumab (Primary)
Indications Clear cell sarcoma; Malignant melanoma; Osteosarcoma; Sarcoma; Solid tumours; Synovial sarcoma
Focus Adverse reactions; Pharmacokinetics

22 Jan 2018 According to a Bristol-Myers Squibb media release, the European Commission (EC) has expanded the indication of Yervoy (ipilimumab) to include treatment of advanced (unresectable or metastatic) melanoma in pediatric patients 12 years of age and older.
03 Nov 2015 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
24 Jan 2012 Planned number of patients changed from 38 to 34 as reported by ClinicalTrials.gov (NCT01445379).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com